Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, has entered a license agreement with Voyager Therapeutics, gaining non-exclusive license to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms include an undisclosed upfront payment, development milestones and a royalty on product sales.
 
“Ablexis welcomes Voyager Therapeutics to the growing list of leading biopharmaceutical companies using the AlivaMab Mouse platform,” said Larry Green, Ph.D., chief executive officer of Ablexis.  “With access to our industry-leading platform, we are excited to work with the Voyager team to help further their mission to discover and develop gene therapies for patients with severe neurological diseases.”

The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR Ts and for a range of applications.